Corrigendum to "Triazolo[4,5- d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells" [Comput. Struct. Biotechnol. J. 16 (2018) 350-360]

Lea Lough; Dan Sherman; Manuel Becerra-Flores; Deepika Vasudevan; Olga Lavinda; Eric Ni; Hong Wang; Hyung Don Ryoo; Raoul Tibes; Timothy Cardozo

doi:10.1016/j.csbj.2020.04.016

Corrigendum to "Triazolo[4,5- d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells" [Comput. Struct. Biotechnol. J. 16 (2018) 350-360]

Comput Struct Biotechnol J. 2020 May 5:18:1092. doi: 10.1016/j.csbj.2020.04.016. eCollection 2020.

Authors

Lea Lough^{1

2}, Dan Sherman^{1

2}, Manuel Becerra-Flores^{1

2}, Deepika Vasudevan^{1

2}, Olga Lavinda^{1

2}, Eric Ni^{1

2}, Hong Wang^{1

2}, Hyung Don Ryoo^{1

2}, Raoul Tibes^{1

2}, Timothy Cardozo^{1

2}

Affiliations

¹ Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
² Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.

Abstract

[This corrects the article DOI: 10.1016/j.csbj.2018.09.003.].

Publication types

Published Erratum